Hepatitis B combination therapy for liver cancer survivors
Part of Cancer, Digestive system clinical trials.
This trial tests a two-drug combination to treat chronic hepatitis B in people who have had liver cancer surgery or ablation. It aims to reduce the virus and improve liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old and expected to live more than 12 months.
- You have had surgery or ablation for liver cancer with no remaining tumors, and your cancer is early stage (BCLC 0 or A).
- You have chronic hepatitis B (positive HBsAg for at least 6 months) and have been on antiviral pills like tenofovir or entecavir for at least a year.
- Your hepatitis B virus level is low (less than 2000 copies/mL) and your HBsAg level is between 10 and 3000 IU/mL.
- Your liver and kidney function, blood counts, and other lab tests are within the required ranges.
- You have no significant liver damage (like cirrhosis or complications) and no other serious medical conditions like other cancers or heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests a new drug called BB102 for people with liver cancer (HCC) that has grown after at least one previous treatment. The drug targets a specific protein (FGF19) that may be fueling the cancer, and doctors want to see if it can shrink tumors or slow the disease.
This Phase 1/2 study tests a lab-made cell treatment (SCG101) for people with hepatitis B–related liver cancer who have already had standard treatments. It aims to shrink tumors and improve outcomes in carefully selected patients.
This study is looking at how well antiviral treatments work to prevent liver cancer in people with chronic hepatitis B who have a family history of the disease. If you are over 30 and taking antiviral medication, you may be able to join.
This trial tests a new combination of medicines to help your body control the hepatitis B virus without needing lifelong treatment. It aims for a 'functional cure,' which means the virus stays inactive and your liver stays healthy.
Hear when a new HBV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.